Advertiment
hsa-miR-29c* Is Linked to the Prognosis of Malignant Pleural Mesothelioma.
Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M, Cohen D, Chajut A, Rosenwald S, Dan H, Benjamin S, Aharonov R.
Authors’ Affiliations: Thoracic Surgery, NYU Langone Medical Center, New York, New York; Department of Pathology, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, Hawaii; and Rosetta Genomics Ltd., Rehovot, Israel.
The inability to forecast outcomes for malignant mesothelioma prevents clinicians from providing aggressive multimodality therapy to the most appropriate individuals who may benefit from such an approach. We investigated whether specific microRNAs (miR) could segregate a largely surgically treated group of mesotheliomas into good or bad prognosis categories. A training set of 44 and a test set of 98 mesothelioma tumors were analyzed by a custom miR platform, along with 9 mesothelioma cell lines and 3 normal mesothelial lines. Functional implications as well as downstream targets of potential prognostic miRs were investigated. In both the training and test sets, hsa-miR-29c* was an independent prognostic factor for time to progression as well as survival after surgical cytoreduction. The miR was expressed at higher levels in epithelial mesothelioma, and the level of this miR could segregate patients with this histology into groups with differing prognosis. Increased expression of hsa-miR-29c* predicted a more favorable prognosis, and overexpression of the miR in mesothelioma cell lines resulted in significantly decreased proliferation, migration, invasion, and colony formation. Moreover, major epigenetic regulation of mesothelioma is mediated by hsa-miR-29c* and was shown through downregulation of DNA methyltransferases as well as upregulation of demethylating genes. A single miR has the potential to be a prognostic biomarker in mesothelioma, and validation of these findings as well as investigation of its downstream targets may give insight for potential therapies in the future. Cancer Res; 70(5); 1916-24.
Leave a Reply
Suggested Posts
Potential New Treatment For Kidney Cancer By Specific Inhibition Of Autophagy hsa-miR-29c* Is Li ked to the Prog osis of Malig a t Pleural Mesothelioma. Pass HI, Goparaju C, Iva ov S, Do i gto J, Carbo e M, Hoshe M, Cohe D, Chajut A, Rose wald S, Da H, Be jami S, Aharo ov R. Authors’ Affiliatio s: Thoracic Surgery, NYU La go e Medical Ce ter, New York, New York; Departme t of Pathology, Ca cer Research Ce ter of Hawaii, U iversity [...]. Posted February 16th, 2010 | 4:15 pm
Treatment Of Gynecologic Cancers Reduced From 5 Weeks To 3 Days Using New Radiation Therapy hsa-miR-29c* Is Li ked to the Prog osis of Malig a t Pleural Mesothelioma. Pass HI, Goparaju C, Iva ov S, Do i gto J, Carbo e M, Hoshe M, Cohe D, Chajut A, Rose wald S, Da H, Be jami S, Aharo ov R. Authors’ Affiliatio s: Thoracic Surgery, NYU La go e Medical Ce ter, New York, New York; Departme t of Pathology, Ca cer Research Ce ter of Hawaii, U iversity [...]. Posted February 16th, 2010 | 4:15 pm
Joint Clinical Practice Guidelines On Hepatocellular Carcinoma Management To Be Published By EASL-EORTC hsa-miR-29c* Is Li ked to the Prog osis of Malig a t Pleural Mesothelioma. Pass HI, Goparaju C, Iva ov S, Do i gto J, Carbo e M, Hoshe M, Cohe D, Chajut A, Rose wald S, Da H, Be jami S, Aharo ov R. Authors’ Affiliatio s: Thoracic Surgery, NYU La go e Medical Ce ter, New York, New York; Departme t of Pathology, Ca cer Research Ce ter of Hawaii, U iversity [...]. Posted February 16th, 2010 | 4:15 pm
Potential Strategy Aims To Stimulate The Immune System To Defeat Cancers hsa-miR-29c* Is Li ked to the Prog osis of Malig a t Pleural Mesothelioma. Pass HI, Goparaju C, Iva ov S, Do i gto J, Carbo e M, Hoshe M, Cohe D, Chajut A, Rose wald S, Da H, Be jami S, Aharo ov R. Authors’ Affiliatio s: Thoracic Surgery, NYU La go e Medical Ce ter, New York, New York; Departme t of Pathology, Ca cer Research Ce ter of Hawaii, U iversity [...]. Posted February 16th, 2010 | 4:15 pm
Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer hsa-miR-29c* Is Li ked to the Prog osis of Malig a t Pleural Mesothelioma. Pass HI, Goparaju C, Iva ov S, Do i gto J, Carbo e M, Hoshe M, Cohe D, Chajut A, Rose wald S, Da H, Be jami S, Aharo ov R. Authors’ Affiliatio s: Thoracic Surgery, NYU La go e Medical Ce ter, New York, New York; Departme t of Pathology, Ca cer Research Ce ter of Hawaii, U iversity [...]. Posted February 16th, 2010 | 4:15 pm